AMED Amedisys

Filed: 10 Jun 21, 4:16pm





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 8, 2021

Commission File Number: 0-24260





Amedisys, Inc.

(Exact name of registrant as specified in charter)




Delaware 11-3131700

(State or other jurisdiction of

incorporation or organization)


(IRS Employer

Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, par value $0.001 per share AMED The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 5.07

Submission of Matters to a Vote of Security Holders.

The Company held its annual meeting of stockholders on Tuesday, June 8, 2021 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals. A brief description of and tabulation of votes for each proposal are set forth below.

Proposal 1. The Company’s stockholders elected the following nine directors for a term of one year. There were 884,088 broker non-votes with respect to the proposal.



  For  Withheld

Vickie L. Capps

  28,034,476  891,840

Molly J. Coye, MD

  28,373,100  553,216

Julie D. Klapstein

  28,117,515  808,801

Teresa L. Kline

  28,301,871  624,445

Paul B. Kusserow

  27,516,239  1,410,077

Richard A. Lechleiter

  28,155,797  770,519

Bruce D. Perkins

  28,372,410  553,906

Jeffrey A. Rideout, MD

  28,373,719  552,597

Ivanetta Davis Samuels

  28,466,386  459,930

Proposal 2. The Company’s stockholders ratified the selection of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2021. There were no broker non-votes with respect to the proposal.


For Against Abstain
29,559,119 224,939 26,346

Proposal 3. The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation paid to the Company’s named executive officers. There were 884,088 broker non-votes with respect to the proposal.


For Against Abstain
27,870,093 1,015,362 40,861


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



/s/ Paul B. Kusserow

Paul B. Kusserow
Chief Executive Officer and Chairman of the Board
DATE: June 10, 2021